How the EU Fails Patients Trying to Access Critical Medicines

A robust agenda to decide the future of healthcare in Europe looms large over the upcoming elections to the European Parliament in May. In the lead up to election day, the current Presidency of the European Union, Romania, has already advocated for an ambitious healthcare plan – including efforts to ensure patients’ access to medicines across the continent.

The unprecedented pace of biomedical research continues to yield new medicines, renewing hope for European patients waiting for better therapies to treat their unmet medical needs. The European Medicines Agency (EMA) is approving more novel drugs every year: in 2018, 42 new active substances were approved by the EMA, an increase from 35 in 2017 and 27 in 2016. These new approvals hold promise for patients in treatments ranging from gene therapies to monoclonal antibodies.

Despite this progress, some patients in Europe are unable to access the medicines they need due to post-approval market access delays throughout the EU. Some medicines can be delayed by an average of 400 days after EMA approval, blocking access to critical medicines for months or even years. In countries where manufacturers command lower prices, such as Poland and EU candidate member Serbia, patients can sometimes wait as long as 1,000 days to receive medicines that have already been approved by the European regulatory authorities.

After securing EMA approval, manufacturers must then negotiate with each individual EU member state to reach pricing and reimbursement agreements. Since pricing procedures differ widely among national health authorities, there are often vast disparities in the time required for a new medicine to enter each European country. Complicating matters, countries with smaller markets often delay negotiations with companies until similar negotiations have been completed in larger markets, whose pricing schemes can provide a ceiling for price negotiations. Given some of the higher prices commanded by new treatments, resource-restricted smaller countries may delay uptake of new drugs in order to defer large payments, despite the impact on patients.

Previous reform efforts have fallen short. In 2012, the European Commission proposed a strict 120-day window for reimbursement determinations to be enforced across all member states – an effort that was supported by European drug manufacturers. But when it was finally adopted, the EU Transparency Directive instead used a 180-day window. This ignores the fact that even a two-month delay can result in unnecessary suffering for patients or death, especially those with life-threatening rare diseases that have no other effective treatment options.

Moreover, the inability of reform efforts to sufficiently address this problem is inconsistent with Europe’s Healthy Ageing goals, which include strengthening European health systems to meet the changing needs of an ageing population and ensuring equal access to quality healthcare, within and between countries.

In recent months, these challenges have only intensified due to the uncertainty around market access for novel medicines that treat rare conditions, called ‘orphan drugs.’ Due to the considerably higher prices commanded by many ‘orphan drugs,’ biopharmaceutical companies and payers have begun to implement value-based payment models to amortise payments and tie them directly to medical outcomes. However, these payment models often lead to prolonged and demanding negotiations, exacerbating delays.

For example, a breakthrough treatment for cystic fibrosis received EMA approval in November 2015 but is still not available in the UK, France, and Spain, and did not enter the German market until December 2016. In England, delays went on for so long that nearly 8,000 packets of the treatment exceeded their 2018 expiry and had to be destroyed, leaving more than 2,800 cystic fibrosis patients waiting to receive treatment.

Similar delays face a different medication to treat spinal muscular atrophy (SMA), which was approved by the EMA in June 2017. By October 2018, few EU markets had reimbursed access for all SMA patients, even though this is the only existing treatment for the disease.

These examples highlight the real-word impact of blocking access to life-altering treatments for patients. EU health authorities must answer a critical question: how can companies and payers negotiate to capture the most value for patients and adhere to cost-effectiveness standards without impeding patient access?

In the absence of an all-encompassing government solution, payers are turning to other strategies to shorten negotiations. In particular, real-world evidence collection has been used to inform payment agreements tied to patient outcomes – a positive first step. This would allow for companies to utilize data from larger European countries to inform product negotiations in smaller states.

9 April marks European Patients’ Rights Day and with that, a reminder that access to high-quality, innovative care is fundamental to European values at the heart of a compassionate, democratic society. The breakneck speed of biomedical innovation and newly approved medicines can only achieve full value if we have unencumbered patient access. Negotiations between healthcare stakeholders should not impede the ultimate stakeholder – patients – from receiving the treatments they so urgently need.

Dr. Hans Groth, MD is President of the World Demographic & Ageing Forum. Dr. Michael Hodin (PhD) is the CEO of the Global Coalition on Aging and Fellow at Harris Manchester College at Oxford University

Source: Euronews

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

New Index Ranking 11 Countries’ Ability to Tackle Rising Threat of Resistance to Antimicrobials Shows Need for Urgent Action

New York, NEW YORK and Washington, DC (June 23, 2021) – Today the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the first-ever global AMR Preparedness Index, a first-of-its-kind evaluation of how the governments of the 11 largest global economies are living up to their commitments to address antimicrobial resistance (AMR).

Global Alliance on Heart Failure & Healthy Aging Unveils New Report Projecting Sharp Rise in Heart Failure Mortality Linked to Population Aging and Missed or Late Diagnosis

New York, NY – June 10, 2021 – Today, the Global Alliance on Heart Failure and Healthy Aging unveiled a new report, Undiagnosed Heart Failure: A Growing Public Health Risk and Looming Financial Iceberg for Aging Societies. The report examines the link between aging and heart failure, recognizing that a significant portion of heart failure deaths occurs in the older population.

Ageism: how age discrimination can be fought in society and the workplace – but older people have to stop believing the stereotypes first

Ageism is something that’s likely to affect everybody as they grow older and it should be treated as seriously as other “isms”, such as racism and sexism. That was the main takeaway from a recent “Solutions to Combat Ageism” webinar, organised in New York by the Global Coalition on Ageing, which aims to educate and drive change to improve older people’s health, productivity and social engagement.

NEW REPORT – Policy Priorities for Super-Ageing Japan: Health Innovation and Economic Growth in the COVID-19 Pandemic Era

New York and Tokyo (February 24, 2021) – Today, the Global Coalition on Aging (GCOA) and the Health and Global Policy Institute (HGPI) announced a report sharing key takeaways from their roundtable on healthy aging, innovation, and the silver economy. The October 2020 virtual roundtable convened experts from across the health, business, aging, and elder homecare sectors in a policy discussion to call on governments to recognize health spending as a critical investment for countries like Japan, who are leading the global megatrend of aging and placing innovation at the center of this investment.

Global Coalition on Aging Partners with the World Summit on the Information Society (WSIS) Forum 2021

New York, NEW YORK (February 23, 2021) – The World Summit on the Information Society (WSIS) Forum 2021 and the Global Coalition on Aging (GCOA) announce their collaboration on the first-ever WSIS Forum Healthy Ageing Innovation Prize to be awarded  at the WSIS Forum 2021.  The prize will be awarded to the most innovative technology that enables healthier and more active ageing and will be presented in parallel with the WSIS Forum 2021 Special Track on ICTs and Older Persons, which is designed, organized and supported by GCOA.

NEW REPORT – The Threat of AMR to Japan’s Super-Aging Society: Implications on Health Care, Public Policy, and Economic Well-Being

New York and Tokyo (February 21, 2021) – Today, the Global Coalition on Aging (GCOA) and the Health and Global Policy Institute (HGPI) announced a report sharing key policy-focused takeaways from their roundtable on antimicrobial resistance (AMR) in super-aging Japan. On October 7, 2020, the roundtable convened experts from across the business, government, academic, aging, and non-profit sectors in a policy discussion that recognized the multifaceted risks of AMR in aging societies around the world, including super-aging Japan.

WSIS Forum 2021 and the Global Coalition on Aging Partner on Hackathon to Inspire Cutting-Edge ICT Innovation for Older Persons

New York, NEW YORK (February 18, 2021) – The World Summit on the Information Society (WSIS) and the Global Coalition on Aging (GCOA) today announce their partnership on the Ageing Better Through ICTs hackathon, a first-of-its-kind global hackathon focused on innovation for the Silver Economy. The hackathon, conducted virtually, will draw participants from around the world and of all ages to generate ideas for information and communication technologies (ICTs) to improve the lives of older persons.

​​​​Global Coalition on Aging and Pfizer Medical Grants Partner to Tackle Vaccine Hesitancy in Super-Aging Japan

New York, NEW YORK (February 17, 2021) – The Global Coalition on Aging and Pfizer Global Medical Grants announced today the launch of the first of its grant projects under the Japan-focused VALUE Initiative (Vaccines for All: Longevity Unleashed for Everyone), which has provided up to $1 million USD in grant awards. Grant recipients include Keio University, the Health and Global Policy Institute (HGPI), and the International Longevity Centre-UK.

Cross-Sector Panel of Experts Offers Trusted Guidance and Answers New Yorkers’ Questions on the Importance of Older Adult New Yorkers Getting Vaccinated Against Covid-19

New York, NEW YORK (January 21, 2021) – The New York City Department for the Aging, the Age-friendly NYC Commission, and the Global Coalition on Aging (GCOA), the world's leading business voice on aging, collaborated yesterday on a webinar to help build trust and acceptance of the Covid-19 vaccines for New York’s older adults.